Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Landscape of costimulatory molecule signature in breast cancer and its prognostic significance. | Ann Transl Med | 2023 | 36819560 | PubTator, text mining | PubMed |
| Molecular classification and therapeutics in diffuse large B-cell lymphoma. | Front Mol Biosci | 2023 | 36818048 | PubTator, text mining | PubMed |
| Construction and comprehensive analysis of a novel prognostic signature associated with pyroptosis molecular subtypes in patients with pancreatic adenocarcinoma. | Front Immunol | 2023 | 36817451 | PubTator, text mining | PubMed |
| Highly expressed CENPL is correlated with breast cancer cell proliferation and immune infiltration. | Front Oncol | 2023 | 36816951 | PubTator, text mining | PubMed |
| Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma. | Front Genet | 2023 | 36816040 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing reveals the immune microenvironment and signaling networks in cystitis glandularis. | Front Immunol | 2023 | 36814917 | PubTator, text mining | PubMed |
| Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration. | FEBS Open Bio | 2023 | 36814419 | PubTator, text mining | PubMed |
| A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms. | Cell Rep Med | 2023 | 36812888 | PubTator, text mining | PubMed |
Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review. | Front Immunol | 2023 | 36798130 | PubTator, text mining | PubMed |
| Signaling pathways in rheumatoid arthritis: implications for targeted therapy. | Signal Transduct Target Ther | 2023 | 36797236 | PubTator, text mining | PubMed |
| Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. | Mol Cancer | 2023 | 36793048 | PubTator, text mining | PubMed |
| Construction and comprehensive analysis of a curoptosis-related lncRNA signature for predicting prognosis and immune response in cervical cancer. | Front Genet | 2023 | 36777734 | PubTator, text mining | PubMed |
| Identification of platinum resistance-related gene signature for prognosis and immune analysis in bladder cancer. | Front Genet | 2023 | 36777726 | PubTator, text mining | PubMed |
| Multi-omics characterization of silent and productive HPV integration in cervical cancer. | Cell Genom | 2023 | 36777180 | PubTator, text mining | PubMed |
| Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. | Nat Commun | 2023 | 36774361 | PubTator, text mining | PubMed |
| A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? | Transl Oncol | 2023 | 36773442 | PubTator, text mining | PubMed |
| CD83 Regulates the Immune Responses in Inflammatory Disorders. | Int J Mol Sci | 2023 | 36769151 | PubTator, text mining | PubMed |
| Comprehensive Analysis of KCNJ14 Potassium Channel as a Biomarker for Cancer Progression and Development. | Int J Mol Sci | 2023 | 36768373 | PubTator, text mining | PubMed |
| The Immunology of DLBCL. | Cancers (Basel) | 2023 | 36765793 | PubTator, text mining | PubMed |
| MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. | Cancers (Basel) | 2023 | 36765782 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=36